L
Lorenzo G. Mantovani
Researcher at University of Milan
Publications - 361
Citations - 38356
Lorenzo G. Mantovani is an academic researcher from University of Milan. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 51, co-authored 324 publications receiving 26740 citations. Previous affiliations of Lorenzo G. Mantovani include University of Naples Federico II & University of Milano-Bicocca.
Papers
More filters
Journal ArticleDOI
Setting dialysis start at 6.0 ml/min/1.73 m2 eGFR—a study on safety, quality of life and economic impact
Lucia Di Micco,Serena Torraca,Andrea Pota,Daniela Di Giuseppe,Antonio Pisani,Letizia Spinelli,Simona de Portu,Massimo Sabbatini,Lorenzo G. Mantovani,Bruno Cianciaruso +9 more
TL;DR: This is the first study evaluating the economic impact of intensive conservative management of CKD stage 5 to postpone start of dialysis in tertiary care and allows a significant amount of time free from dialysis, with good QoL and major savings in the costs of nation's dialysis budget.
Journal ArticleDOI
Assessment of Outcomes Among Patients With Venous Thromboembolism With and Without Chronic Kidney Disease
Shinya Goto,Sylvia Haas,Walter Ageno,Samuel Z. Goldhaber,Alexander G.G. Turpie,Jeffrey I. Weitz,Pantep Angchaisuksiri,Joern Dalsgaard Nielsen,Gloria Kayani,Alfredo E. Farjat,Sebastian Schellong,Henri Bounameaux,Lorenzo G. Mantovani,Paolo Prandoni,Ajay K. Kakkar,Garfield-Vte investigators +15 more
TL;DR: The study’s findings suggest that patients with venous thromboembolism and concomitant moderate to severe chronic kidney disease had worse prognoses, and further investigation is warranted to evaluate options for anticoagulation therapy.
Journal ArticleDOI
Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options
Paolo Cortesi,A. Ciaccio,Matteo Rota,Joseph K. Lim,S. De Salvia,S. Okolicsanyi,Maria Cristina Vinci,Luca S. Belli,Lorenzo G. Mantovani,Mario Strazzabosco,Mario Strazzabosco +10 more
TL;DR: In view of anticipated improvement in the efficacy of future regimens, selective treatment of only patients with advanced fibrosis and cirrhosis with TVR or BOC could represent the most cost‐effective strategy to optimize resource utilization.
Journal ArticleDOI
Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.
Sergio Iannazzo,Paolo Cortesi,Roberto Crea,Katharina Nora Steinitz,Lorenzo G. Mantovani,Alessandro Gringeri +5 more
TL;DR: Pharmacokinetic-driven prophylaxis, accounting for patients’ individual pharmacokinetic variability, appears to be a promising strategy to improve outcomes with efficient use of available resources in severe haemophilia A patients.
Journal ArticleDOI
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery.
Alexander G.G. Turpie,André C Schmidt,Reinhold Kreutz,Michael R. Lassen,Waheed Jamal,Lorenzo G. Mantovani,Sylvia Haas +6 more
TL;DR: XAMOS will supplement the clinical data obtained in the Phase III RECORD 1, 2, 3, and 4 trials in which rivaroxaban was shown to be superior for the primary efficacy endpoints, and with a safety profile similar to that of enoxaparin after hip or knee replacement surgery.